Abeona Therapeutics Inc Market Cap ($241.32 Million)
Market Cap & Net Worth: Abeona Therapeutics Inc (ABEO)
Abeona Therapeutics Inc market cap. Abeona Therapeutics Inc (NASDAQ:ABEO) has a market capitalization of $241.32 Million ($241.32 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15625 globally and #3726 in its home market, demonstrating a -5.17% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Abeona Therapeutics Inc's stock price $4.22 by its total outstanding shares 57184017 (57.18 Million). Also see Abeona Therapeutics Inc (ABEO) cash flow conversion for how efficiently the company converts equity into cash flow.
Abeona Therapeutics Inc Market Cap History (2015–2026)
Abeona Therapeutics Inc market cap history from 2015 to 2026. Data shows change from $4.80 Billion to $241.32 Million (-25.01% CAGR). Check Abeona Therapeutics Inc stock price for real-time trading data and today's change.
Index Memberships
Abeona Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.01% | #419 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #1530 of 3165 |
Weight: Abeona Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Abeona Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Abeona Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Abeona Therapeutics Inc growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
51.78x
Abeona Therapeutics Inc's market cap is 51.78 times its annual revenue
Latest Price to Earnings (P/E) Ratio
4.23x
Abeona Therapeutics Inc's market cap is 4.23 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $6.93 Billion | $889.00K | -$21.87 Million | 7799.28x | N/A |
| 2017 | $22.66 Billion | $837.00K | -$27.32 Million | 27071.88x | N/A |
| 2018 | $10.21 Billion | $3.00 Million | -$56.67 Million | 3404.72x | N/A |
| 2020 | $2.24 Billion | $10.00 Million | -$84.23 Million | 224.45x | N/A |
| 2021 | $481.78 Million | $3.00 Million | -$84.94 Million | 160.59x | N/A |
| 2022 | $176.13 Million | $1.41 Million | -$39.70 Million | 124.56x | N/A |
| 2023 | $286.49 Million | $3.50 Million | -$54.19 Million | 81.85x | N/A |
| 2025 | $301.36 Million | $5.82 Million | $71.18 Million | 51.78x | 4.23x |
Competitor Companies of ABEO by Market Capitalization
Companies near Abeona Therapeutics Inc in the global market cap rankings as of November 5, 2026. Also see ABEO total asset value for a full breakdown of the balance sheet.
Key companies related to Abeona Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Abeona Therapeutics Inc (2015–2026)
Market capitalization of Abeona Therapeutics Inc from 2015 to today. Between 2015 and today, Abeona Therapeutics Inc's market cap moved from $4.80 Billion to $ 241.32 Million, with a yearly change of -25.01%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $241.32 Million | -19.92% |
| 2025 | $301.36 Million | -5.39% |
| 2024 | $318.51 Million | +11.18% |
| 2023 | $286.49 Million | +62.66% |
| 2022 | $176.13 Million | -63.44% |
| 2021 | $481.78 Million | -78.54% |
| 2020 | $2.24 Billion | -51.99% |
| 2019 | $4.67 Billion | -54.20% |
| 2018 | $10.21 Billion | -54.95% |
| 2017 | $22.66 Billion | +226.80% |
| 2016 | $6.93 Billion | +44.35% |
| 2015 | $4.80 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Abeona Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $241.32 Million USD |
| MoneyControl | $241.32 Million USD |
| MarketWatch | $241.32 Million USD |
| marketcap.company | $241.32 Million USD |
| Reuters | $241.32 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Abeona Therapeutics Inc
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of starga… Read more